<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04878718</url>
  </required_header>
  <id_info>
    <org_study_id>19343</org_study_id>
    <nct_id>NCT04878718</nct_id>
  </id_info>
  <brief_title>Vancomycin and Fecal Microbiota Transplant in a Single Patient With Autism Spectrum Disorder</brief_title>
  <official_title>Vancomycin and Fecal Microbiota Transplant in a Single Patient for the Treatment of Autism Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProgenaBiome</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Topelia Therpeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ProgenaBiome</source>
  <brief_summary>
    <textblock>
      Single patient with ASD will be treated with Vancomycin followed by FMT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single patient with profound ASD will be treated with Vancomycin. This will be followed by&#xD;
      fecal microbiota transplant. The patient will be followed for one year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Autism Spectrum Disorder</condition>
  <condition>Autism</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplant; Vancomycin</intervention_name>
    <description>Subject will be treated with vancomycin followed by fecal microbiota transplant</description>
    <other_name>FMT</other_name>
    <other_name>vancomycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Autism Spectrum Disorder&#xD;
&#xD;
          2. Parent or Legally Authorized Representative willing and able to provide informed&#xD;
             consent&#xD;
&#xD;
          3. A reliable caregiver who can report side effects and communicate effectively with the&#xD;
             research team&#xD;
&#xD;
          4. Stable medications in the two months prior to enrollment&#xD;
&#xD;
          5. Currently receiving interventions in the community/school for ASD&#xD;
&#xD;
          6. If female and of childbearing potential, must be willing to utilize at least one&#xD;
             highly effective method of birth control for the duration of the study. This includes&#xD;
             condoms with spermicide, oral birth control pills, contraceptive implants,&#xD;
             intra-uterine devices, or diaphragms. Subjects not of reproductive potential will be&#xD;
             exempt (e.g. post-menopausal, surgically sterilized)&#xD;
&#xD;
          7. If male, and partner is of childbearing potential, must be willing to utilize at least&#xD;
             one highly effective method of birth control for the duration of the study. This&#xD;
             includes condoms with spermicide, oral birth control pills, contraceptive implants,&#xD;
             intra-uterine devices, or diaphragms. Subjects not of reproductive potential will be&#xD;
             exempt (surgically sterilized)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subjects who are pregnant, nursing, or intend to become pregnant during the&#xD;
             study period.&#xD;
&#xD;
          2. Subjects whose caregivers are unable/unwilling to cooperate with the protocol&#xD;
             requirements.&#xD;
&#xD;
          3. Subject will be excluded who are suffering with Rett syndrome and Childhood&#xD;
             Disintegrative Disorder.&#xD;
&#xD;
          4. Other serious co-morbid medical disorders affecting brain function and behaviour,&#xD;
             including uncontrolled seizures.&#xD;
&#xD;
          5. Subjects unable to refrain from taking non-study antibiotics for the period of the&#xD;
             study.&#xD;
&#xD;
          6. Subjects diagnosed with cancer, except small localized basal cell carcinoma.&#xD;
&#xD;
          7. Subjects known to abuse alcohol or drugs.&#xD;
&#xD;
          8. Subjects who have undergone gastric bypass or total colectomy, or who are scheduled&#xD;
             for these procedures.&#xD;
&#xD;
          9. Infection with HIV.&#xD;
&#xD;
         10. Infection with Hepatitis B or C.&#xD;
&#xD;
         11. Allergy to benzodiazepine.&#xD;
&#xD;
         12. Inability to stop loperamide, diphenoxylate/atropine, or cholestyramine before the&#xD;
             study&#xD;
&#xD;
         13. Unable to stop opiate treatment unless on a stable dose including PRN dosing, and no&#xD;
             dose increase planned for the duration of the study&#xD;
&#xD;
         14. Known positive stool cultures for enteropathogens including, but not limited to&#xD;
             Shigella, Salmonella, and Campylobacter within 30 days before enrollment.&#xD;
&#xD;
         15. Known stool studies positive for ova and/or parasites in 30 days prior to enrollment.&#xD;
&#xD;
         16. Planned travel outside United States during study period.&#xD;
&#xD;
         17. Hypersensitivity to vancomycin&#xD;
&#xD;
         18. Renal insufficiency&#xD;
&#xD;
         19. Colitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Sabine Hazan, MD</last_name>
    <role>Study Director</role>
    <affiliation>ProgenaBiome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Hazan, MD</last_name>
    <phone>805-339-0549</phone>
    <email>drsabinehazan@progenabiome.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jordan E Daniels, MS</last_name>
    <phone>805-339-0549</phone>
    <email>jordan@progenabiome.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ventura Clinical Trials</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Sabine Hazan, MD</last_name>
      <phone>805-339-0549</phone>
      <email>drsabinehazan@progenabiome.com</email>
    </contact>
    <contact_backup>
      <last_name>Jordan E Daniels, MS</last_name>
      <phone>18053390549</phone>
      <email>jordan@progenabiome.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fecal Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

